OBJECTIVES: High-dose atorvastatin crystalline has been shown to reduce the risk of recurrent stroke among patients with a recent stroke/TIA. It was found to be a cost-effective treatment strategy in many countries; however, there is no data available in Thailand. This study examined the cost-effectiveness of atorvastatin crystalline 80 mg/day compared to usual treatment in prevention of recurrent stroke in Thailand. METHODS: A discrete event simulation was used to project long-term results of atorvastatin crystalline reported in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. A clinical course following a stroke or TIA was simulated based on the risks of stroke and cardiovascular events observed from the trial adjusted by baseline demographics and risk factors of Thai patients. Costs and resource use were obtained from Chulalongkorn Stroke Database, life expectancy from Saskatchewan Health Database, and utility weights from a literature. Costs, survival, and quality-adjusted life-years (QALYs) were estimated over lifetime from a health-care provider perspective; discounted 3% annually. RESULTS: Compared to usual care, using atorvastatin crystalline resulted in a decrease in numbers of stroke, TIA, MI, angina and other cardiovascular events which led to an average gain of 0.28 QALYs and 0.27 survival years per patient. A net additional cost of atorvastatin crystalline resulting from higher drug costs and reduction in direct medical costs was 182,910 baht/patient, or 483,800 baht/QALY (US $14,229) gained. Subgroup analyses indicated that lower ICERs (396,000-464,000 baht/QALY or US$11,647-US$12,470) have been shown in high risks patients (e.g., older age, history of stroke/ TIA, diabetes, hypertension). CONCLUSIONS: For patients with prior stroke/TIA, using atorvastatin crystalline comparing to current post-stroke care is clinically effective in Thai stroke patients. ICER is slightly in excess of three times of GDP/capita (US$11,920) as the threshold recommended by WHO, however, it still can be considered economically tolerable as a cost-effective use was found in specifi c patient groups.
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PCV19 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP AND KNEE REPLACEMENT (THR, TKR) IN CHINESE PATIENTS
Chen XB 1 , Eggington S 2 , Wang CY 3 , Zhu M 4 1 School of Public Health, Fudan University, Shanghai, Shanghai, China; 2 IMS Health, London, UK; 3 IMS China, Beijing, China; 4 Bayer Healthcare Company Ltd., Beijing, China OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban against enoxaparin for prevention of venous thromboembolism (VTE) after total hip (THR) and knee (TKR) replacement in China. METHODS: An economic model was developed, consisting of three modules: prophylaxis, post-prophylaxis, and long-term complications. The fi rst two modules were represented using a decision tree while the third module used a Markov process. Safety and effi cacy data during prophylaxis were derived from a pooled analysis of Chinese patients enrolled in two phase III registration trials (RECORD 2 and 3). Utility outcomes and the probability of long-term events were based on systematic review and published data. Resource use related to VTE prevention, treatment and complications was based on clinical guidelines, product labels, and interviews conducted in six Tier 3 hospitals in Beijing, Shanghai and Guangzhou City. Unit cost data were collected from the government pricing bureau presented in 2009 CNY from the health-care system perspective. Costs and outcomes were discounted at 3% per annum. Extensive one-way and probabilistic sensitivity analyses were undertaken. RESULTS: In the base case analyse, rivaroxaban was shown to be dominant compared with enoxaparin. Rivaroxaban was associated with 0.0065 additional QALYs per patient while saving an average of CNY 232 per patient over 5 years. Probabilistic sensitivity analyses estimated that rivaroxaban is more effective and less expensive in 57.8% of all stochastic model runs. The probability of rivaroxaban being cost-effective was 60% with a willingness-to-pay threshold of CNY 20,000 per QALY and 80% with a threshold of CNY 100,000. CONCLUSIONS: Compared with enoxaparin in a pooled analysis of Chinese patients, rivaroxaban improved health outcomes and produced cost savings in VTE prevention after TKR and THR in China. Sensitivity analyses indicated the results of model are robust. The most cost-effective option for cardiovascular disease prevention in people with 10-year risks of 5% and greater was the polypill followed by combinations of three blood pressure drugs with or without a statin. Single generic drugs, except angiotensin reuptake blockers were also very cost-effective, but dominated by drug combinations due to greater health gain and shared costs. Sensitivity Analysis: All generic drugs except beta blockers and angiotensin reuptake blockers, and the above combinations were very cost-effective; the median cost effectiveness ratios for all of these drugs were below one times gross domestic product per capita in people with 10-year risks of 5% and greater. CON-CLUSIONS: Primary cardiovascular disease prevention with a combination of generic drugs in Thailand is very cost-effective when the 10-year absolute risk is 5% or higher.
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PCV21 MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH DIAGNOSTIC AND PROGNOSTIC INFORMATION
Priest VL 1 , Scuffham PA 2 , Marwick T 3 1 Griffi th University, Brisbane, Queensland, Australia; 2 Griffi th University, Meadowbrook, Queensland, Australia; 3 University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: Most Emergency Room (ER) presentations with chest pain are unrelated to coronary artery disease (CAD). Coronary computed tomography (CT) has been proposed to allow earlier exclusion and discharge of patients at low risk of CAD, resulting in cost-savings in the management of chest pain. Knowing the expected health outcomes, costs and cost-effectiveness of new diagnostic tests is important, but few comparative trials are undertaken and modeling is often required. Prognostic information links test results to long-term risks of events and mortality, and is the most relevant information for risk-stratifi cation and predicting patient outcomes. However, head-to-head trials of diagnostic techniques are uncommon, and may be confounded by underlying patient characteristics and prevalence of disease in the trial population. In contrast, diagnostic accuracy information can be adapted to predict the expected occurrence of false diagnoses in a tested population by using epidemiological formulas that incorporate the underlying disease prevalence rate. METHODS: A decision-analytic model was designed to compare CT with exercise-stress testing using echocardiography (ExE) or single-photon emitting computed tomography (SPECT) using the available diagnostic and prognostic evidence. Epidemiological formulas were used to determine the initial proportion of the population that tested positive and negative, and determined clinical management of patients who tested positive for CAD. Long-term outcomes were modeled using hard-event rates (myocardial infarction and mortality) in clinical trials that report 12-month follow-up of patients tested with each diagnostic test. RESULTS: The results indicate CT may be associated with a higher rate of events in patients with an initial negative test, which would negate some of the cost-savings from faster initial diagnosis. The analysis is sensitive to the rate, and consequences, of misdiagnosis. CONCLUSIONS: More information on the prognosis of patients with an initial negative CT test is needed before this strategy is accepted to be cost-saving in the diagnosis of chest pain. Comparison of cost-effectiveness of rivaroxaban with dabigatran in prevention of venous thromboembolism (VTE) in patients after total hip replacement (THR) from payer perspective in Slovakia. METHODS: In a cost-utility model results of two large randomized controlled trials were used. Patients in both studies received 35 days prophylaxis regimen: in RECORD 1 with rivaroxaban or enoxaparin and in RE-NOVATE with dabigatran or enoxaparin. Indirect comparison in metaanalysis showed that rivaroxaban reduced total VTE by 64% and symptomatic VTE by 82% versus dabigatran. Three parts of model represents prophylaxis, post-prophylaxis, and long-term complications. Data from RECORD 1 and RE-NOVATE trials are used for fi rst part of the model. Published epidemiological and clinical data estimating the risk of further VTE events and post-thrombotic syndrome beyond the trial period were used in second and third part of the model. Published price lists (2010) were used for local cost data. Utilities related to VTE were derived from literature. Time horizon was set at 5 years and payers perspective was used. Quality-adjusted life-years (QALY) were chosen for effectiveness measurement and discount rate of 5% per year for costs and effects was applied according to valid guidelines for health economic evaluation in Slovakia. One-way and probabilistic sensitivity analyses were performed. RESULTS: Rivaroxaban showed cost-effectiveness versus dabigatran, with a small cost reduction of 0.46f and a QALY gain of 0.0016 per patient. In probabilistic analysis 84.3% of simulations were below 18,000f/QALY, which is offi cially published threshold for willingness to pay in Slovakia. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to dabigatran for the prevention of VTE following THR in Slovakian setting.
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